Ignite Creation Date:
2024-05-06 @ 4:03 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02440893
Status:
COMPLETED
Last Update Posted:
2019-01-31
First Post:
2015-05-06
Brief Title:
Understanding the Effect of Metformin on Corus CAD or ASGES
Sponsor:
CardioDx
Organization:
CardioDx
Study Overview
Official Title:
Understanding the Effect of Metformin on Corus CAD MET Study
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MET
Brief Summary:
The study goal was to understand the effect of Metformin on AgeSexGene Expression Score ASGES or Corus CAD henceforth Corus in pre-diabetic patients who are medication naive This study provided data to determine if the Corus CAD ASGES signature was different in pre-diabetic patients when metformin was newly prescribed and taken
Detailed Description:
The study goal was to understand the effect of Metformin on AgeSexGene Expression Score ASGES or Corus CAD in pre-diabetic patients who are medication naive This study provided data to determine if the Corus CAD ASGES signature was different in pre-diabetic patients when metformin was newly prescribed and taken The primary aim of this study was to evaluate whether metformin used in pre-diabetic patients to prevent progression to type II diabetes had a significant effect on the gene expression levels measured in Corus This was a prospective study Subjects were enrolled from participating sites as applicable inclusionexclusion criteria were met The study aimed to enroll approximately fifty 50 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MET Study | OTHER | CardioDx | None |